STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment

STAT PlusBiotech Preliminary trial results suggest a path to a safer Alzheimer’s treatment ProMIS Neurosciences thinks it can clear amyloid from the brain with lower side effect risks than approved medicines Manage alerts for this article Email this article Share this article By Adam FeuersteinJuly 28, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. An interim look at an Alzheimer’s disease clinical trial evaluating an amyloid-targeting treatment from ProMIS Neurosciences showed low rates of brain bleeding and no incidences of brain swelling — results reported Tuesday that suggest the drug could be safer than approved treatments. In a blinded analysis that pooled safety data from patients receiving the ProMIS drug and a placebo, the total rate of ARIA was 4.4%, with all cases mild and asymptomatic, the company said. Advertisement None of the patients experienced ARIA-E, which is the more severe side effect that causes brain swelling. All the cases were characterized as ARIA-H, which involves tiny bleeds in the brain. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Alzheimer’s, biotechnology, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Recommended Health July 28, 2026 From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD Health Care Inc. Newsletter July 27, 2026 STAT Plus: Pharma’s drug spending deflection Advertisement Biotech July 27, 2026 STAT Plus: Sarepta names Michael Severino, former Tessera CEO, as new chief executive Biotech July 27, 2026 STAT Plus: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug Biotech July 27, 2026 STAT Plus: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease Subscriber Picks